Commentary on the "Evidence- and Consensus-Based (S3) Guidelines for the Treatment of Actinic Keratosis" Published by the International League of Dermatological Societies in Cooperation with the European Dermatology Forum.
- Diepgen TL Department of Clinical Social Medicine, Occupational and Environmental Dermatology, Heidelberg University Hospital, Heidelberg, Germany.
- Kresken J Irmgardis Pharmacy, Viersen, Germany.
- Krutmann J IUF - Leibniz Institute for Environmental Research, Düsseldorf, Germany.
- Merk HF Department of Dermatology and Allergology, University Hospital, Aachen, Germany.
- Senger E Dermatology practice, Seligenstadt, Germany.
- Surber C Departments of Dermatology Clinics, University Hospitals, Basel, Switzerland.
- Szeimies RM Department of Dermatology and Allergology, Clinic Vest, Recklinghausen, Germany.
- 2018-04-04
Published in:
- Skin pharmacology and physiology. - 2018
Actinic keratosis
Evidence-based medicine
International guideline
National guideline
Patient groups
Society for Dermopharmacy
Treatment recommendations
Consensus
Dermatology
Evidence-Based Medicine
Humans
Keratosis, Actinic
Practice Guidelines as Topic
Skin Neoplasms
English
In 2015, the International League of Dermatological Societies and the European Dermatology Forum published a guideline for the treatment of actinic keratosis, which is classified as an evidence- and consensus-based S3 guideline. From the point of view of the GD Task Force "Licht.Hautkrebs.Prävention," an interdisciplinary expert panel of the Society for Dermopharmacy for the prevention and treatment of skin cancer, this guideline reveals strengths and weaknesses but, in summary, does not meet the claim for an evidence- and consensus-based S3 guideline.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1159/000486687
- PMID 29614495
- Persistent URL
- https://sonar.ch/global/documents/232288
Statistics
Document views: 41
File downloads:
- Full-text: 0